The Clinical Efficacy and Safety of Ertapenem for the Treatment of Complicated Urinary Tract Infections Caused by ESBL-Producing Bacteria in Children
المؤلفون المشاركون
Karaaslan, Ayse
Soysal, Ahmet
Bakır, Mustafa
Öcal Demir, Sevliya
Akkoc, Gulsen
Yakut, Nurhayat
Atici, Serkan
Kepenekli Kadayifci, Eda
المصدر
International Journal of Nephrology
العدد
المجلد 2015، العدد 2015 (31 ديسمبر/كانون الأول 2015)، ص ص. 1-4، 4ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2015-05-27
دولة النشر
مصر
عدد الصفحات
4
التخصصات الرئيسية
الملخص EN
Background.
Urinary tract infections (UTIs) are common and important clinical problem in childhood, and extended-spectrum-beta-lactamase- (ESBL-) producing organisms are the leading cause of healthcare-related UTIs.
In this study, we aimed to evaluate the clinical efficacy and safety of ertapenem therapy in children with complicated UTIs caused by ESBL-producing organisms.
Methods.
Seventy-seven children with complicated UTIs caused by ESBL-producing organisms were included in this retrospective study, and all had been treated with ertapenem between January 2013 and June 2014.
Results.
Sixty-one (79%) females and sixteen (21%) males with a mean ± standard deviation (SD) age of 76.6 ± 52 months (range 3–204, median 72 months) were enrolled in this study.
Escherichia coli (E.
coli) ( n = 67 ; 87%) was the most common bacterial cause of the UTIs followed by Klebsiella pneumoniae (K.
pneumoniae) ( n = 9 ; 11.7%) and Enterobacter cloacae (E.
cloacae) ( n = 1 ; 1.3%).
The mean duration of the ertapenem therapy was 8.9 ± 1.6 days (range 4–11).
No serious drug-related clinical or laboratory adverse effects were observed, and the ertapenem therapy was found to be safe and well tolerated in the children in our study.
Conclusion.
Ertapenem is a newer carbapenem with the advantage of once-daily dosing and is highly effective for treating UTIs caused by ESBL-producing microorganisms.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Karaaslan, Ayse& Kepenekli Kadayifci, Eda& Atici, Serkan& Akkoc, Gulsen& Yakut, Nurhayat& Öcal Demir, Sevliya…[et al.]. 2015. The Clinical Efficacy and Safety of Ertapenem for the Treatment of Complicated Urinary Tract Infections Caused by ESBL-Producing Bacteria in Children. International Journal of Nephrology،Vol. 2015, no. 2015, pp.1-4.
https://search.emarefa.net/detail/BIM-1066234
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Karaaslan, Ayse…[et al.]. The Clinical Efficacy and Safety of Ertapenem for the Treatment of Complicated Urinary Tract Infections Caused by ESBL-Producing Bacteria in Children. International Journal of Nephrology No. 2015 (2015), pp.1-4.
https://search.emarefa.net/detail/BIM-1066234
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Karaaslan, Ayse& Kepenekli Kadayifci, Eda& Atici, Serkan& Akkoc, Gulsen& Yakut, Nurhayat& Öcal Demir, Sevliya…[et al.]. The Clinical Efficacy and Safety of Ertapenem for the Treatment of Complicated Urinary Tract Infections Caused by ESBL-Producing Bacteria in Children. International Journal of Nephrology. 2015. Vol. 2015, no. 2015, pp.1-4.
https://search.emarefa.net/detail/BIM-1066234
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1066234
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر